secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longevity Health Holdings, Inc. (XAGE)
CIK:        0001842939
Form:       8-K
Filed at:   2025-05-21T23:59:59+00:00
Accession:  0000950170-25-075865
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq panel grants conditional continued listing for Longevity Health pending merger with 20/20 Biolabs by Sept 2, 2025
--------------------------------------------------------------------------------

- Nasdaq Hearings Panel granted continued listing condition: complete merger with 20/20 Biolabs and meet initial listing rules by Sept 2, 2025.
- Company filed S-4 for merger on May 8, 2025, and effected 1-for-30 reverse stock split on May 12, 2025.
- Panel based decision on review of financial statements and pro forma projections of combined company.
- Chairman/CEO Rajiv Shukla stated focus on completing merger to satisfy Nasdaq requirements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842939/000095017025075865/0000950170-25-075865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842939/000095017025075865/xage-20250520.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-075865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer